Omeprazole A2845: Practical Research Protocol

Omeprazole, SKU A2845, is a research compound used to study proton pump inhibition, gastric acid secretion, and antiulcer responses. The compound is identified in the product dossier as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, with a molecular weight of 345.42 and molecular formula C17H19N3O3S. The supplied dossier reports H+,K+-ATPase inhibition with an IC50 of 5.8 μM and inhibition of histamine-induced acid formation with an IC50 of 0.16 μM.

Because no directly matched paper evidence is available for this request, the guidance below separates product specifications from workflow recommendations. It is intended to support reproducible gastric acid secretion research, antiulcer activity study design, and exploratory peptic ulcer disease model workflows without implying clinical efficacy.

The Omeprazole product page from APExBIO should be checked alongside the certificate of analysis and the laboratory protocol before use. For related handling context, Omeprazole (A2845): Technical Guidance for Research Use complements this article by emphasizing research-only scope, solubility, and stability controls. For assay-specific implementation, Omeprazole (A2845): Technical Guidance for Gastric Acid Research provides related workflow framing for gastric acid secretion and peptic ulcer disease model studies.

What This Product Solves

Many gastric acid secretion workflows need a defined inhibitor to establish whether an observed signal depends on H+,K+-ATPase activity. Omeprazole addresses that experimental need by providing a characterized small molecule for enzyme, cell-based, tissue, and preclinical assay development, provided that the selected model has been validated for compound exposure and response measurement.

The principal practical challenge is not simply adding inhibitor to a well or tissue preparation. Omeprazole is insoluble in water and ethanol, while the dossier reports solubility of at least 17.27 mg/mL in DMSO. Consequently, solvent selection, vehicle matching, mixing, and precipitation checks are central to data quality. The compound should be treated as a research reagent for comparative assay conditions, not as an antiulcer agent for patient treatment or as a validated intervention for gastric acid-related disorders.

Its reported IC50 values can help define an initial assay-planning range, but they should not be copied directly into every system. Apparent potency depends on assay format, substrate or tissue preparation, exposure time, protein content, endpoint definition, and compound availability at the target site. Use the dossier values as orientation points and determine assay-specific response behavior experimentally.

Protocol Parameters

Protocol Parameters

• Assay: H+,K+-ATPase inhibition  |  Value: IC50 5.8 μM  |  Applicability: Proton pump or enzyme-based assay planning  |  Rationale: Provides a dossier-reported potency reference for constructing a concentration-response experiment; it is not a universal working concentration.  |  Evidence basis: Product dossier.
• Assay: Histamine-induced acid formation  |  Value: IC50 0.16 μM  |  Applicability: Gastric acid secretion assays using a histamine-stimulated endpoint  |  Rationale: Supports selection of a relevant assay benchmark when the experimental system reproduces the stated stimulation context.  |  Evidence basis: Product dossier.
• Assay: Primary stock preparation  |  Value: DMSO solubility ≥17.27 mg/mL; water and ethanol insoluble  |  Applicability: In vitro stock preparation and dilution workflows  |  Rationale: DMSO is the dossier-supported solvent for preparing a concentrated stock; inspect the stock and final dilution for visible precipitation.  |  Evidence basis: Product dossier.
• Assay: Compound identity and normalization  |  Value: Molecular weight 345.42; formula C17H19N3O3S  |  Applicability: Molar concentration calculations, sample records, and cross-run normalization  |  Rationale: Use the stated molecular weight and formula when converting mass-based preparation records to molar units.  |  Evidence basis: Product dossier.
• Assay: Storage and shipment  |  Value: Solid storage at -20°C; blue ice shipment for small molecules  |  Applicability: Receipt, inventory, and long-term solid-state storage  |  Rationale: Maintain the solid under the stated condition and avoid treating long-term solution storage as equivalent; the dossier does not recommend it.  |  Evidence basis: Product dossier.
• Assay: Release-quality review  |  Value: Approximately 98% purity  |  Applicability: Batch acceptance and interpretation of concentration-response data  |  Rationale: Record the lot-specific quality information and avoid presenting nominal concentration as an absolute measure of active compound exposure.  |  Evidence basis: Product dossier.

Workflow Setup and QC Checklist

1. Confirm the material. Record SKU A2845, lot information, stated purity, molecular weight, formula, receipt condition, and storage location. Retain the certificate of analysis with the experiment record.
2. Prepare the vehicle correctly. Because the compound is insoluble in water and ethanol, prepare the primary stock in DMSO. Add the stock to the assay matrix gradually with adequate mixing. Examine the resulting solution for haze, crystals, or droplets before dosing cells, membranes, tissue, or enzyme preparations.
3. Control solvent exposure. Use a vehicle control containing the same final DMSO exposure as treated samples. Keep the vehicle constant across the concentration series whenever possible so that acid secretion or viability changes are not confused with solvent effects.
4. Build an assay-specific range. Use the dossier-reported IC50 values only as starting orientation. Include concentrations that span below and above the expected response region, then confirm whether the assay reaches a stable baseline and a reproducible inhibited state. Do not equate an IC50 with a recommended dose.
5. Standardize stimulation and timing. In a histamine-induced acid formation assay, keep the histamine challenge, preincubation, exposure interval, temperature, and endpoint readout consistent between runs. For other gastric acid secretion research formats, document the stimulation condition rather than assuming transferability from the histamine value.
6. Use appropriate controls. Include untreated or baseline controls, vehicle controls, and a positive assay control when one has already been qualified in the laboratory. For tissue or cell studies, monitor viability or preparation integrity independently from the acid-related endpoint.
7. Protect the material from avoidable instability. Store the solid at -20°C as specified. Prepare only the solution volume needed for the planned work, and do not rely on long-term storage of the solution form. Record preparation time, solvent, appearance, and any freeze-thaw or handling events.
8. Document the endpoint. Report nominal concentration, vehicle percentage, exposure duration, assay matrix, stimulation state, replicate structure, and any precipitation observation. These details are essential when comparing results across gastric acid secretion inhibitor workflows.

Common Failure Modes and Fixes

Visible precipitation after dilution

Likely cause: The aqueous or mixed assay environment cannot maintain the selected compound concentration, or the DMSO stock was added too quickly. Fix: Verify complete dissolution in DMSO before dilution, add stock gradually under mixing, reduce the selected concentration if justified by the assay plan, and reject samples with visible precipitate unless the protocol explicitly validates particulate exposure.

Vehicle-dependent assay changes

Likely cause: Treated wells receive a different final DMSO exposure from controls. Fix: Normalize the vehicle across all conditions and include a vehicle-only control. If the assay is sensitive to solvent, establish solvent tolerance before interpreting inhibition.

Loss of apparent potency between runs

Likely cause: Extended solution storage, repeated handling, inconsistent preparation time, or changes in assay matrix. Fix: Prefer freshly prepared working solutions, minimize unnecessary storage, retain the solid at -20°C, and record preparation and exposure timing. Compare runs only after confirming matched controls and assay conditions.

Inconsistent inhibition in tissue or cell models

Likely cause: Variable tissue integrity, pump expression, stimulation strength, or endpoint timing. Fix: Qualify the biological preparation independently, standardize the stimulation procedure, and analyze the response relative to within-run controls rather than relying only on the nominal IC50.

Overinterpretation of a single numeric value

Likely cause: Treating the dossier IC50 as transferable across all systems. Fix: Describe the value as a product-dossier benchmark, generate an assay-specific concentration-response curve, and report the experimental context with the result.

Scope and Limitations

This material is for scientific research use only and is not intended for diagnostic, therapeutic, or medical application. The supplied information supports work on H+,K+-ATPase inhibition, gastric acid secretion research, antiulcer activity study design, and selected peptic ulcer disease model workflows. It does not establish clinical benefit, safety, pharmacokinetics, or suitability for human or veterinary use.

The dossier provides identity, purity, solubility, storage, shipping, and selected potency values, but it does not define a universal cell dose, tissue dose, incubation time, formulation, or validated readout for every model. Researchers should qualify these parameters locally and consult current institutional chemical-safety procedures. Results should not be extended to unrelated biological systems without direct validation.

Conclusion

Omeprazole A2845 is most useful when treated as a controlled research reagent rather than as a ready-made clinical model intervention. Reliable results depend on DMSO-based preparation, vehicle matching, precipitation checks, solid-state storage at -20°C, assay-specific concentration-response testing, and careful separation of product specifications from workflow assumptions. These controls provide a practical foundation for reproducible proton pump inhibition and gastric acid-related disorder research in the absence of directly matched paper evidence.